Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin(R) for acromegaly and neuroendocrine tumors

BASEL, Switzerland, NEW YORK and JERUSALEM, Feb. 18, 2013 -- (Healthcare Sales & Marketing Network) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-az-ma) Inc., a privately held biopharma company, announced today that they have entered i... Biopharmaceuticals, Endocrinology, LicensingChiasma, Roche Group, Octreolin, acromegaly
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news